CN105596646B - Medicine, health-care product or food composition for controlling blood glucose and treating abnormal blood lipid metabolism - Google Patents
Medicine, health-care product or food composition for controlling blood glucose and treating abnormal blood lipid metabolism Download PDFInfo
- Publication number
- CN105596646B CN105596646B CN201510813258.8A CN201510813258A CN105596646B CN 105596646 B CN105596646 B CN 105596646B CN 201510813258 A CN201510813258 A CN 201510813258A CN 105596646 B CN105596646 B CN 105596646B
- Authority
- CN
- China
- Prior art keywords
- rhizoma dioscoreae
- compositionss
- crude drug
- fructus lycii
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention provides a medicine, health-care product or food composition composed of Chinese wolfberry, Chinese yam and a crude drug A, wherein the crude drug A is selected from one of prepared rehmannia root, rhizoma polygonati and radix polygonati officinalis. The composition can control blood glucose and/or treat abnormal blood lipid metabolism, has exact curative effect, is available to suit the remedy to the case, is convenient to prepare, and almost has no waste of the crude drug.
Description
Technical field
The invention belongs to Chinese medicine, health product or field of food, specifically, the present invention relates to controlling blood glucose and treatment blood fat
The medicine of Developmental and Metabolic Disorder, health product or food compositions and its preparation and application.
Background technology
Hyperglycemia, hyperlipidemia and obesity etc. are " affluenza " leading under modern life custom, especially type ii diabetes people
Often with Anomalous lipid metablism, there is presently no the means of radical cure, need Long-term taking medicine or take health food controlling and
Improve.
Prior art also has many formula based on Chinese crude drug to control blood glucose, blood fat and liver function, but they are often
It is limited by raw material (crude drug) species excessive, formula is complicated, the quality of production is difficult to control to.For example, Chinese Patent No. 96116603
Number disclose a kind of blood sugar lowering electuary and preparation method thereof, it include Fructus Cucurbitae moschatae powder, precision corn, Testa Tritici, the Radix Astragali, Radix Puerariae, Radix Rehmanniae,
Rhizoma dioscoreae, Stigma Maydis, Fructus Mori, Fructus Lycii, activated calcium, xylitol, Margarita powder, stevioside, Semen Sesami Nigrum etc.；Chinese Patent No.
No. 200510020632 disclose a kind of Amti-sanility health-care food, it include Rhizoma Dioscoreae, Poria, Semen Coiciss, Fructus Crataegi, Semen Cassiae or what
The Radix Polygoni Multiflori or Radix Et Rhizoma Rhei, Semen Armeniacae Amarum or Semen Persicae, Thallus Laminariae (Thallus Eckloniae), Concha Ostreae, SEMEN COAT GLYCINES NIGRUM, Rhizoma Polygonati, Fructus Lycii, Fructus Rubi；Chinese Patent No.
No. 201210034191 disclose a kind of Fructus Canarii lipid-loweringingization sugar granule and its preparation technology, and wherein raw material is：Fructus Canarii, Fructus Momordicae charantiae, yellow
Stilbene, Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong, Endothelium Corneum Gigeriae Galli, Rhizoma Dioscoreae, Fructus Crataegi, Fructus Lycii, Rhizoma Polygonati, Folium Mori.In addition, the curative effect of the formula of prior art is generally not
Too definite, and for disease, the patient's condition very generally it is difficult to suit the remedy to the case for specific patient.
The present inventor through long-term and arduous research, some fortune in addition, be surprisingly based on Fructus Lycii, mountain
The formula of medicine, Radix Rehmanniae Preparata, Rhizoma Polygonati and/or Rhizoma Polygonati Odorati, wherein crude drug species only have 2 or 3 kind, preparation process is simple, are easy to control and produce
Quality, and determined curative effect, can significantly control blood glucose and/or treatment dysbolism of blood fat etc., more surprisingly, no
Same formula is very strong to the specific aim of disease, the patient's condition, is therefore adapted to concrete patient, suits the remedy to the case.
In addition, processed to put into practice by doctor trained in Western medicine reductionism thought and the traditional Chinese medical science being affected, prior art generally carrying using crude drug
Take thing (as extractive with organic solvent etc.) to be used as medicine, not only crude drug utilization rate is limited, and period can produce a large amount of waste residues and/
Or waste liquid, also can carry organic solvent residual in medicine, and the present inventor is not confined by such prior art completely,
Develop new preparation method, take full advantage of crude drug to greatest extent, any harmful substance (e.g., You Jirong can not be introduced
Agent), keep the pure natural property of product, and in preparation process, be nearly free from any waste residue and/or waste liquid, be particularly suitable for existing
Carry out large-scale production in the case of modern pay attention to day by day environmental pollution.
Content of the invention
It is an object of the invention to provide new medicine, health product or food compositions, it can be used as staple food succedaneum
It is eaten for a long time, for controlling blood glucose and/or treatment dysbolism of blood fat etc..In addition, present invention also offers the system of said composition
Preparation Method, product and application etc..
Specifically, in a first aspect, the invention provides medicine, health product or food compositions, it is by Fructus Lycii, Rhizoma Dioscoreae
With crude drug A composition, wherein crude drug A is selected from one of Radix Rehmanniae Preparata, Rhizoma Polygonati and Rhizoma Polygonati Odorati, and wherein Fructus Lycii, Rhizoma Dioscoreae and crude drug A
Weight is than for 55～65：160～200：0～18.
Herein, medicine, health product and food are all known to various equivalent modifications, be referred to food and
The definition of drug regulatory department and standard.For example, in the present invention, crude drug (raw material) and preparation just meet drug standard
Can be considered as composite medicine, and only meet food standard is then food compositions.
Herein, raw material or crude drug are known to various equivalent modifications.For example, Fructus Lycii also known as Fructus Lycii, ripe
Radix Rehmanniae also known as Radix Rehmanniae Preparata etc., these raw materials or crude drug all can pass through open market purchase.
Preferably in the compositionss of first aspect present invention, the weight of Fructus Lycii, Rhizoma Dioscoreae and crude drug A is than for 58～63：170～
190：0～16, more preferably 60：180：0～15, in the specific embodiment of the invention, can be 60：180：0、60：180：
5、60：180：10 or 60：180：15.In the compositionss of first aspect present invention, the amount of crude drug A can be 0, i.e. the present invention
The compositionss of one side can be made up of Fructus Lycii and Rhizoma Dioscoreae, it is preferred, therefore, that the compositionss of first aspect present invention are by Fructus Lycii and mountain
Medicine forms, and the weight ratio of wherein Fructus Lycii and Rhizoma Dioscoreae is for 55～65：160～200, preferably 58～63：170～190, more excellent
Elect 60 as：180, such as 60：180.
The in addition, it is also preferred that compositionss of first aspect present invention are made up of Fructus Lycii, Rhizoma Dioscoreae and Radix Rehmanniae Preparata, and wherein Chinese holly
The weight of Qi, Rhizoma Dioscoreae and Radix Rehmanniae Preparata is than for 55～65：160～200：3～6, preferably 58～63：170～190：4～6, more
It is preferably 60：180：5.It is also preferred that the compositionss of first aspect present invention are made up of Fructus Lycii, Rhizoma Dioscoreae and Rhizoma Polygonati, and wherein Chinese holly
The weight of Qi, Rhizoma Dioscoreae and Rhizoma Polygonati is than for 55～65：160～200：8～12；It is also preferred that the compositionss of first aspect present invention are by Chinese holly
Qi, Rhizoma Dioscoreae and Rhizoma Polygonati Odorati composition, and the weight ratio of wherein Fructus Lycii, Rhizoma Dioscoreae and Rhizoma Polygonati Odorati is for 55～65：160～200：13～18, excellent
Elect 58～63 as：170～190：15～16, more preferably 60：180：15.
The present inventor's research finds, directly Fructus Lycii, Rhizoma Dioscoreae and crude drug A is mixed (e.g., being pulverized and mixed), mouthfeel is bad, treats
Effect also appears to be affected.For this reason, the well-designed preparation method of the compositionss of first aspect present invention of the present inventor, gram
Take drawbacks described above, and most efficiently can utilize all crude drugs, hardly introduced other materials during preparation, can keep
The pure natural property of product of the present invention, is also nearly free from garbage (including waste residue and/or waste liquid).It is therefore preferable that the present invention
The compositionss of one side, it is prepared by the following method：
(1) Rhizoma Dioscoreae and crude drug A are added water to cook, then cool down；
(2) solid obtaining step (1) and liquid are mixed with Fructus Lycii and carry out homogenate and pulverize；With,
(3) ground product that step (1) obtains is dried, is then optionally pulverized again.
Further, it is preferable to wherein, the weight of water is 2～3.5 times of the gross weight of Rhizoma Dioscoreae and crude drug A, preferably 3 times.
Also further, it is preferable to wherein, the time of decoction is 20～60 minutes, preferably 30 minutes.
Also further, it is preferable to wherein, cool down the temperature reaching and be 20～30 DEG C, preferably room temperature.Herein, as no
Contradiction or special instruction, room temperature can be 25 DEG C.
In second aspect, the invention provides the preparation method of the compositionss of first aspect present invention, it includes：
(1) Rhizoma Dioscoreae and crude drug A are added water to cook, then cool down；
(2) solid obtaining step (1) and liquid are mixed with Fructus Lycii and carry out homogenate and pulverize；With,
(3) ground product that step (1) obtains is dried, is then optionally pulverized again.
Preferably in the preparation method of second aspect present invention, the weight of water be the gross weight of Rhizoma Dioscoreae and crude drug A 2～
3.5 times, preferably 3 times.
It is also preferred that in the preparation method of second aspect present invention, the time of decoction is 20～60 minutes, preferably 30 points
Clock.
It is also preferred that in the preparation method of second aspect present invention, cooling down the temperature reaching and be 20～30 DEG C, preferably room
Temperature.Herein, as noncontradictory or special instruction, room temperature can be 25 DEG C.
In the preparation method of second aspect present invention, homogenate pulverizing can be carried out with equal pulp grinder, and drying can be with cold
Carrying out, these are all the equipment that can buy on open market to lyophilizer.
In the third aspect, the invention provides medicine, health product or food compositions, it includes the group of first aspect present invention
Acceptable adjuvant on compound and medicine, on health product or on food.Herein, on medicine, on health product or can on food
The adjuvant accepting refer respectively to Fructus Lycii, Rhizoma Dioscoreae and crude drug A compatible and do not affect they play effects nontoxic medicine,
Health product or food adjuvant, including carrier, excipient, diluent and flavoring agent etc..
In fourth aspect, the invention provides the preparation method of the product of third aspect present invention, it is included the present invention
The compositionss of first aspect and the step on medicine, on health product or together with acceptable auxiliary material combination on food.
The compositionss of first aspect present invention and adjuvant are combined, various preparations (that is, product) can be configured to,
Be preferably solid preparation and liquid preparation, such as tablet, pill, capsule (include sustained release or postpone to release releasing pattern), powder,
The dosage forms such as suspensoid, granule, tincture, syrup, emulsion agent, suspension, injection and various slow release formulation, thus be suitable for each
Kind of form of medication, for example oral, parenteral injection, mucosa, muscle, intravenouss, subcutaneous, ophthalmic, Intradermal or through skin etc.
Form of medication, most preferably oral.Optional adjuvant includes dispersant, such as nanorize dispersant, such as nano-starch, nanometer paste
Essence, Nano-meter SiO_22, Nano-meter CaCO33, nano-TiO2, nano zine oxide, nanometer indium, nanometer silver, nano-aluminum hydroxide, nano oxidized
Ferrum, nanometer iron chloride, nano-sized carbon, nanometer selenium, nano aluminium oxide, nano magnesia.Other suitable adjuvants include Polyethylene Glycol
Class, polyvidone class water-solubility carrier, such as PEG2000-20000 or PVP K15-K90 or PVA or PVP-PVA or CPD etc..At this
In the specific embodiment of invention, adjuvant can be water, so can keep the pure natural property of product of the present invention.
At the 5th aspect, the invention provides the compositionss of first aspect present invention reduce blood glucose in preparation (especially eating
Blood glucose afterwards) level, reduce serum total cholesterol level, reduce serum triglyceride level, reduce serum low-density LP water
The flat, application reducing in serum GPT levels and/or medicine, health product or the food of reduction liver index.
The inventors discovered that the different formula determined curative effects finely tuned in the compositionss of first aspect present invention, to disease, disease
The specific aim of condition is very strong, is therefore adapted to concrete patient, suits the remedy to the case.It is therefore preferable that the application in fifth aspect present invention
In, described compositionss are made up of Fructus Lycii, Rhizoma Dioscoreae and Rhizoma Polygonati, and the weight of wherein Fructus Lycii, Rhizoma Dioscoreae and Rhizoma Polygonati is than for 55～65：
160～200：8～12, preferably 58～63：170～190：9～11, more preferably 60：180：10；Wherein said medicine, guarantor
Strong product or food reduce serum total cholesterol level, reduce serum triglyceride level and/or reduce serum low-density LP
Level.Should be particularly well-suited to reduce the above-mentioned patient's condition but not otherwise by the compositionss that Fructus Lycii, Rhizoma Dioscoreae and Rhizoma Polygonati form
The patient of the patient's condition (e.g., liver function is normal, need not reduce serum GPT levels), can avoid to otherwise unfavorable
Impact.
It is also preferred that in the application of fifth aspect present invention, described compositionss are made up of Fructus Lycii, Rhizoma Dioscoreae and Rhizoma Polygonati Odorati, Er Qieqi
The weight of middle Fructus Lycii, Rhizoma Dioscoreae and Rhizoma Polygonati Odorati is than for 55～65：160～200：13～18, preferably 58～63：170～190：15～
16, more preferably 60：180：15；Wherein said medicine, health product or food reduce serum low-density LP level, reduce blood
Clear gpt level and/or reduction liver index.Should be particularly well-suited to by the compositionss that Fructus Lycii, Rhizoma Dioscoreae and Rhizoma Polygonati Odorati form
There is the disease reducing the above-mentioned patient's condition but not having the otherwise patient's condition (e.g., total cholesterol level is normal, triglyceride levels are normal)
People, can avoid to otherwise adverse effect.
It is also preferred that in the application of fifth aspect present invention, described compositionss are made up of Fructus Lycii and Rhizoma Dioscoreae, and wherein Chinese holly
The weight of Qi and Rhizoma Dioscoreae is than for 55～65：160～200, preferably 58～63：170～190, more preferably 60：180；Wherein institute
State medicine, health product or food and reduce liver index.Should be particularly well-suited in reduction by the compositionss that Fructus Lycii and Rhizoma Dioscoreae form
State the patient's condition but there is no the otherwise patient's condition that (e.g., total cholesterol level is normal, triglyceride levels are normal, serum low-density fat
Protein level is normal) patient, can avoid to otherwise adverse effect.
In addition, preferably in the application of fifth aspect present invention, reducing blood glucose (especially post-prandial glycemia) level is immediately to rise
Effect.Therefore in corresponding application, food can be appetizer before the meal.
The beneficial effects of the present invention is, in formula, crude drug species is few, preparation process is simple, is easy to control product quality,
And determined curative effect；Blood glucose and/or treatment dysbolism of blood fat etc. can significantly be controlled, especially different formula is to disease, disease
The specific aim of condition is very strong, is adapted to concrete patient, suits the remedy to the case；Preparation process takes full advantage of crude drug to greatest extent, can
Not introduce any harmful substance, keep the pure natural property of product, and be nearly free from preparation process any waste residue and/or
Waste liquid, very environmental protection.
The present invention refer to existing open source literature, and these documents are their full text in order to more clearly describe the present invention
Content is all included herein, just look like their full text herein repeated description excessively the same.In order to make it easy to understand, with
Under will present invention is described by specific embodiment.It is important to note that what these descriptions were merely exemplary
Description, and be not meant to limit the scope of the invention.Using the method described in the embodiment of the present invention, it is also possible to obtain the present invention
Other technical schemes.According to the discussion of this specification, many changes of the present invention, change are for one of ordinary skill in the art
It is all obviously.
Specific embodiment
Crude drug in specific examples below and equipment etc. are from the purchase of open market channel.
The formula for a product of embodiment 1 present invention and its preparation
1st, HH003 preparation technology
(1) Rhizoma Dioscoreae is cleaned, weigh Rhizoma Dioscoreae 180g, plus 540ml (3 times amount) water, decoct 30min, put to room temperature, put into ice
Case cold preservation, standby.
(2) weigh Fructus Lycii 60.0g, put in refiner, above-mentioned standby Rhizoma Dioscoreae and decoction liquor are put in refiner, low speed
Pulverize 1min, then high speed pulverization 1min, be repeated 4 times.
(3) pour in lyophilized plate, lyophilization, pulverize, obtain final product the dry powder of HH003.
(4) weigh HH003 dry powder, with water as wetting agent, wetting agent consumption is 15%, No. 1 sieve series grain, 50 DEG C of drying 2h, 1
Number sieve granulate.
2nd, HH003S preparation technology
(1) Rhizoma Dioscoreae is cleaned, weigh Rhizoma Dioscoreae 180g, Radix Rehmanniae Preparata 5g, plus 555ml (3 times amount) water, decoct 30min, put to room
Temperature, puts into refrigerator cold-storage, standby.
(2) weigh Fructus Lycii 60.0g, put in refiner, above-mentioned standby Rhizoma Dioscoreae, Radix Rehmanniae Preparata and decoction liquor are put into refiner
In, low speed pulverizes 1min, then high speed pulverization 1min, is repeated 4 times.
(3) pour in lyophilized plate, lyophilization, pulverize, obtain final product the dry powder of HH003S.
(4) weigh HH003S dry powder, with water as wetting agent, wetting agent consumption is 15%, No. 1 sieve series grain, 50 DEG C of drying 2h,
No. 1 sieve granulate.
3rd, HH003H preparation technology
(1) Rhizoma Dioscoreae is cleaned, weigh Rhizoma Dioscoreae 180g, Rhizoma Polygonati 10g, plus 570ml (3 times amount) water, decoct 30min, put to room
Temperature, puts into refrigerator cold-storage, standby.
(2) weigh Fructus Lycii 60.0g, put in refiner, above-mentioned standby Rhizoma Dioscoreae, Rhizoma Polygonati and decoction liquor are put into refiner
In, low speed pulverizes 1min, then high speed pulverization 1min, is repeated 4 times.
(3) pour in lyophilized plate, lyophilization, pulverize, obtain final product the dry powder of HH003H.
(4) weigh HH003H dry powder, with water as wetting agent, wetting agent consumption is 15%, No. 1 sieve series grain, 50 DEG C of drying 2h,
No. 1 sieve granulate.
4th, HH003Y preparation technology
(1) Rhizoma Dioscoreae is cleaned, weigh Rhizoma Dioscoreae 180g, Rhizoma Polygonati Odorati 15g, plus 585ml (3 times amount) water, decoct 30min, put to room
Temperature, puts into refrigerator cold-storage, standby.
(2) weigh Fructus Lycii 60.0g, put in refiner, above-mentioned standby Rhizoma Dioscoreae, Rhizoma Polygonati Odorati and decoction liquor are put into refiner
In, low speed pulverizes 1min, then high speed pulverization 1min, is repeated 4 times.
(3) pour in lyophilized plate, lyophilization, pulverize, obtain final product the dry powder of HH003Y.
(4) weigh HH003Y dry powder, with water as wetting agent, wetting agent consumption is 15%, No. 1 sieve series grain, 50 DEG C of drying 2h,
No. 1 sieve granulate.
The short-term drug effect clinical observation to hyperglycemia patient Postprandial glucose control for the product of embodiment 2 present invention
The post-prandial glycemia of the type ii diabetes people of insulin insensitivity, is the important indicator of abnormal carbohydrate metabolism, therefore this reality
Apply example by the detection of such patient's post-prandial glycemia is investigated with the blood sugar decreasing effect of medicine.According to state food drug administration
The execution of clinical trial standard, patient to random packet (age 45-56 year, three one group of people, its fasting glucose 7.5mM/L
More than, more than 10mM/L after the meal) distinguish HH003 prepared by oral administration embodiment 1, HH003Y, HH003H, dosage is with above-mentioned powder
Or granule meter, it is 30g.On before lunch take medicine after 30min, patient take food 30g decocting in water Semen Maydiss, after 2h chemically examine blood glucose, result is such as
Shown in table 1 below.
Result shows, HH003, HH003Y and HH003H to hyperglycemia patient post-prandial glycemia by significant control action,
Life-time service does not report side effect and untoward reaction (e.g., easily sweat and lose hair), and they can onset immediately, test
During all good is represented to the mouthfeel of these products, be therefore particularly suitable as appetizer etc..
Before and after table 1 medication/nonuser dining, blood glucose compares
Note：F：Women M：Male's blood sugar lowering ratio："-" is blood glucose rise
The product of embodiment 3 present invention merges the pharmacodynamics test of rats with nonalcoholic fatty liver disease to type 2 diabetes mellitus
HH003, HH003Y, HH003H, the HH003S of Example 1 preparation, being configured to concentration with 0.5%CMC-Na is
The solution for standby of 50mg/ml.
Take 60 Wistar rats (male, body weight 180-200g, feeding environment：SPF level Animal House, freely ingests, 12h
Illumination/12h is dark), adaptability is raised 1 week.In the 2nd week, Normal group (10) and modeling are randomly divided into according to body weight
Group (60), Normal group feed normal feedstuff, modeling group feed high-sugar-fat-diet.After modeling 4 weeks, modeling group abdominal cavity is noted
Penetrate streptozotocin (Streptozocin, STZ) 25mg/kg and continue high fat diet, Normal group equal-volume intraperitoneal injection
Citric acid-sodium citrate buffer simultaneously continues normal diet, the 9th weekend, and Rat Fast overnight, measures fasting glucose (FBG) and contains
Amount and insulin content (Fins) calculate insulin index (ISI), with fasting glucose>11.1rnmol/L and ISI reduction is thought
Model is successfully established.Measure simultaneously the blood lipid level (TC, TG, LDL-C, HDL-C, FFA) of each group rat and liver function (ALT,
AST、TB).Successful for modeling rat is randomly divided into model group, HH003 group, HH003Y group, HH003H group, HH003S group, often
Group 10, single cage is raised.Each administration group gavage gives relative medicine (dosage is 500mg/kg in terms of dry powder), continuously gives
Medicine 4 weeks.During this period in addition to Normal group feed normal feedstuff, remaining each group still feed high-sugar-fat-diet.Measure weekly
Rat body weight, water is can't help in fasting after last dose, rat weight after 12h, and femoral artery takes blood, separates serum, measures total in serum
Cholesterol (TC), triglyceride (TG), low density lipoprotein, LDL (LDL-C) level, and measure serum glutamic pyruvic transminase (ALT) water
Flat, in addition take liver organization, weigh, calculate liver index.
Product of the present invention is as shown in table 2 to the result of the test of blood fat.Compared with Normal group, in model group rats blood
TC, TG, LDL-C significantly raise (p<0.05), hints model HypercholesterolemicRats Rats are disorderly.Compared with model group, HH003H
Group Serum TC, TG, LDL-C level significantly reduce (p<0.05)；HH003Y group rat blood serum LDL-C level significantly reduces (p
<0.05).
The impact to blood fat for table 2. product of the present invention (N=10).
#p<0.05, compare with Normal group；*p<0.05, compare with model group
Product of the present invention is as shown in table 3 to the result of the test of liver.Compared with Normal group, the liver of model group rats
Index, serum ALT activities significantly raise (p<0.05), hints model Liver Function occurs extremely.Compared with model group,
HH003 group rat liver index significantly reduces (p<0.05)；HH003Y group rat liver index and serum ALT activities all have significantly
Reduce (p<0.05).
The impact to liver index of correlation for table 3. product of the present invention (N=10).
#p<0.05, compare with Normal group；*p<0.05, compare with model group.
Claims (25)
1. medicine, health product or food compositions, it is made up of Fructus Lycii, Rhizoma Dioscoreae and crude drug A, and wherein crude drug A is selected from Radix Rehmanniae Preparata, Huang
Essence and one of Rhizoma Polygonati Odorati, and the weight ratio of wherein Fructus Lycii, Rhizoma Dioscoreae and crude drug A is for 60：180：0～15.
2. the compositionss described in claim 1, the wherein weight of Fructus Lycii, Rhizoma Dioscoreae and crude drug A are than for 60：180：0.
3. the compositionss described in claim 1, the wherein weight of Fructus Lycii, Rhizoma Dioscoreae and crude drug A are than for 60：180：5、60：180：10
Or 60：180：15.
4. the compositionss described in claim 1, it is prepared by the following method：
(1) Rhizoma Dioscoreae and crude drug A are added water to cook, then cool down；
(2) solid obtaining step (1) and liquid are mixed with Fructus Lycii and carry out homogenate and pulverize；With,
(3) ground product that step (1) obtains is dried, is then optionally pulverized again.
5. the compositionss described in claim 4, wherein, the weight of water is 2～3.5 times of the gross weight of Rhizoma Dioscoreae and crude drug A.
6. the compositionss described in claim 5, wherein, the weight of water is 3 times of the gross weight of Rhizoma Dioscoreae and crude drug A.
7. the compositionss described in claim 4, wherein, the time of decoction is 20～60 minutes.
8. the compositionss described in claim 7, wherein, the time of decoction is 30 minutes.
9. the compositionss described in claim 4, wherein, cool down the temperature reaching and are 20～30 DEG C.
10. the compositionss described in claim 9, wherein, cooling down the temperature reaching is room temperature.
The preparation method of the compositionss of 11. claim 4, it includes：
(1) Rhizoma Dioscoreae and crude drug A are added water to cook, then cool down；
(2) solid obtaining step (1) and liquid are mixed with Fructus Lycii and carry out homogenate and pulverize；With,
(3) ground product that step (1) obtains is dried, is then optionally pulverized again.
Preparation method described in 12. claim 11, wherein, the weight of water is 2～3.5 times of the gross weight of Rhizoma Dioscoreae and crude drug A.
Preparation method described in 13. claim 12, wherein, the weight of water is 3 times of the gross weight of Rhizoma Dioscoreae and crude drug A.
Preparation method described in 14. claim 11, wherein, the time of decoction is 20～60 minutes.
Preparation method described in 15. claim 14, wherein, the time of decoction is 30 minutes.
Preparation method described in 16. claim 11, wherein, cools down the temperature reaching and is 20～30 DEG C.
Preparation method described in 17. claim 16, wherein, cooling down the temperature reaching is room temperature.
18. medicines, health product or food compositions, it includes in arbitrary compositionss and medicine of claim 1～10, health product
Acceptable adjuvant on upper or food.
Arbitrary compositionss of 19. claim 1～10 reduce blood sugar level, reduce serum total cholesterol level, fall in preparation
Low serum triglyceride level, reduction serum low-density LP level, reduction serum GPT levels and/or reduction
Application in the medicine of liver index, health product or food.
Application described in 20. claim 19, wherein blood glucose are post-prandial glycemia.
Application described in 21. claim 19, wherein said compositionss are made up of Fructus Lycii, Rhizoma Dioscoreae and Rhizoma Polygonati, and wherein Fructus Lycii,
The weight of Rhizoma Dioscoreae and Rhizoma Polygonati is than for 60：180：10, wherein said medicine, health product or food reduction serum total cholesterol level,
Reduce serum triglyceride level and/or reduce serum low-density LP level.
Application described in 22. claim 19, wherein said compositionss are made up of Fructus Lycii, Rhizoma Dioscoreae and Rhizoma Polygonati Odorati, and wherein Fructus Lycii,
The weight of Rhizoma Dioscoreae and Rhizoma Polygonati Odorati is than for 60：180：15, wherein said medicine, health product or food reduce serum low-density LP water
Put down, reduce serum GPT levels and/or reduce liver index.
Application described in 23. claim 19, wherein said compositionss are made up of Fructus Lycii and Rhizoma Dioscoreae, and wherein Fructus Lycii and Rhizoma Dioscoreae
Weight than for 60：180, wherein said medicine, health product or food reduce liver index.
Application described in 24. claim 19, wherein reducing blood sugar level is instant onset.
Application described in 25. claim 24, wherein blood glucose are post-prandial glycemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510813258.8A CN105596646B (en) | 2014-11-27 | 2015-11-20 | Medicine, health-care product or food composition for controlling blood glucose and treating abnormal blood lipid metabolism |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410691904 | 2014-11-27 | ||
| CN2014106919043 | 2014-11-27 | ||
| CN201510813258.8A CN105596646B (en) | 2014-11-27 | 2015-11-20 | Medicine, health-care product or food composition for controlling blood glucose and treating abnormal blood lipid metabolism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105596646A CN105596646A (en) | 2016-05-25 |
| CN105596646B true CN105596646B (en) | 2017-02-22 |
Family
ID=55977373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510813258.8A Active CN105596646B (en) | 2014-11-27 | 2015-11-20 | Medicine, health-care product or food composition for controlling blood glucose and treating abnormal blood lipid metabolism |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105596646B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106511968A (en) * | 2016-11-23 | 2017-03-22 | 武汉百思凯瑞纳米科技有限公司 | Selenium-rich oral solution with effects of reducing blood sugar, reducing blood fat and boosting immunity and preparation method thereof |
| CN107041558A (en) * | 2017-06-20 | 2017-08-15 | 慧谷生命科技湖北有限公司 | A kind of Poria cocos radix polygonati officinalis meal replacement powder suitable for diabetes |
| CN109200183A (en) * | 2017-07-03 | 2019-01-15 | 无限极（中国）有限公司 | A kind of herbal composite and preparation method thereof and product |
| US11957726B2 (en) * | 2017-09-08 | 2024-04-16 | Beijing Hebabiz Biotechnology Co., Inc. | Pharmaceutical composition for controlling blood sugar |
| CN110731508A (en) * | 2019-11-14 | 2020-01-31 | 南充观音山农业科技有限公司 | Preparation method of traditional Chinese medicine food for enhancing human immunity and product |
| CN114766628A (en) * | 2022-05-21 | 2022-07-22 | 温州岁安健康食品有限公司 | Meal replacement powder for diabetics to eat and preparation method thereof |
| CN116531459A (en) * | 2023-05-30 | 2023-08-04 | 中国医学科学院药用植物研究所 | Preparation method and application of rhizoma polygonati and Chinese wolfberry pills |
| CN118286349A (en) * | 2024-04-10 | 2024-07-05 | 山西献果园生物科技股份有限公司 | Traditional Chinese medicine composition with blood sugar regulating function and preparation method and application thereof |
-
2015
- 2015-11-20 CN CN201510813258.8A patent/CN105596646B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105596646A (en) | 2016-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105596646B (en) | Medicine, health-care product or food composition for controlling blood glucose and treating abnormal blood lipid metabolism | |
| CN103736063A (en) | Medicinal diet for regulating damp-heat constitution and preparation method thereof | |
| WO2014007760A1 (en) | Seven-star tea without excipient and method of preparing the same | |
| CN104126746A (en) | Blood sugar-reducing and blood lipid-reducing dendrobium officinale kimura et migo composition and preparation method thereof | |
| CN105749179A (en) | Traditional Chinese medicine composition for treating metabolic syndrome | |
| CN103736064A (en) | Medicated diet for conditioning phlegm-dampness constitution, and preparation method thereof | |
| CN104288644A (en) | Pharmaceutical composition for treating spleen deficiency and preparation method thereof | |
| CN1618446A (en) | Medicine for treating diabetes, and its prepn. method | |
| CN102600358B (en) | Traditional Chinese laxative medicine and product thereof | |
| CN105266149A (en) | Herba dendrodii officinalis compound health-care capsule and preparation method thereof | |
| CN106177183A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, green tea and Folium Mori | |
| CN104587429B (en) | A kind of Rhizoma Zingiberis Recens honey concocts Radix Panacis Quinquefolii preparation and preparation method | |
| CN101524441A (en) | Chinese medicinal composition for lipid-lowering and weight-losing and preparation method thereof | |
| CN106176952A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja and Folium Ilicis | |
| CN102038927A (en) | Pharmaceutical composition for preventing and treating climacteric metancholia and other diseases | |
| CN103463554A (en) | Pharmaceutical composition for treating malignant tumor, preparation method and application | |
| CN103690832B (en) | A kind of Chinese medicine composition for the treatment of viral myocarditis | |
| CN102188612A (en) | Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof | |
| CN104587175B (en) | A kind of Chinese medicine preparation for treating diabetes | |
| CN104055963B (en) | A kind of fat reducing Chinese medicine composition and preparation method | |
| CN102048146A (en) | Healthcare food with functions of beautifying, skin-care, yellow-removing, antiagingand preparation method thereof | |
| CN105327115A (en) | Phellinus linteus catharsis formula for prevention and cure of type II diabetes and preparation process thereof | |
| CN103989983A (en) | Black sesame and sophora flavescens effervescent tablet and preparation method thereof | |
| CN103705868B (en) | One treats hyperthyroid pharmaceutical composition and application thereof | |
| CN103751255A (en) | Pachymaran composition for decreasing blood sugar and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |